Dr Ana-Mishel (AM) Spiroski and Ziad Mallat
Dec 18, 2025, 23:22
Dr Ana-Mishel (AM) Spiroski Shares Ziad Mallat’s Article: Translating Nobel Prize-Winning Treg Cell Science Into Cardiovascular Therapy
Dr Ana-Mishel (AM) Spiroski, Cardiovascular TA Lead, Age-Related Diseases TA Lead, Group Leader, In Vivo Pharmacology at Evotec, quoted Ziad Mallat’s post on LinkedIn:
“This is one of the most exciting areas in cardiovascular drug development. A fantastic comment by Professor Zallat Cambridge Cardiovascular on the potential of immune tolerance in cardiovascular therapeutics.”
Quoting Ziad Mallat’s post:
“Here’s the full PDF of the comment published in Nature Cardiovascular Reserach. Translating Nobel Prize-winning Treg cell science into cardiovascular therapy.”
Read full article here.
Follow the latest in Hemostasis Today.
-
May 5, 2026, 16:28Nikolay Novitski: A New Era in Cardiovascular Prevention
-
May 5, 2026, 16:23Satyam Arora: Best Abstract Award in Pediatric Apheresis at ASFA 2026 Congress
-
May 5, 2026, 16:17Hannah Omunakwe: Your Sick Child Has a Clot. Did You See That Coming?
-
May 5, 2026, 15:57Venous Thromboembolism Risk in Pregnancy and the Postpartum Period – NBCA
-
May 5, 2026, 15:28Soumen Bhattacharyya: Hyperhomocysteinemia and Thrombosis – What Clinicians Should Know
-
May 5, 2026, 15:06Wolfgang Miesbach: How Should We Approach GI Angiodysplasia in VWD?
-
May 5, 2026, 14:48What Constitutes High Risk for Venous Thromboembolism? – JTH
-
May 5, 2026, 14:41How Real-Time Data, Rehabilitation Registries, and Patient-Reported Outcomes Can Transform Practice – European Stroke Organisation
-
May 5, 2026, 14:41Driving National Change for Bleeding Disorders – WFH